Abeona therapeutics® announces publication in the lancet of phase 3 viital™ study data in recessive dystrophic epidermolysis bullosa

- rdeb is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant clinical burden, including pain, itch, and risk of squamous cell carcinoma -

ABEO Ratings Summary

ABEO Quant Ranking